Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. MAZE | 0.00 |
- Maze Therapeutics outlined a kidney and metabolic disease pipeline, led by MZE829, a selective APOL1 inhibitor for APOL1-mediated kidney disease.
- Phase 2 HORIZON initial data showed a 36% mean uACR reduction across 12 evaluable patients; 50% achieved at least a 30% reduction.
- Non-diabetic patients showed a 49% mean uACR reduction; the FSGS subset showed a 62% mean reduction, supporting plans for a pivotal program.
- Additional HORIZON data targeted for late 2026 or early 2027; pivotal trial initiation targeted for 1H 2027, subject to regulatory feedback.
- Cash runway expected into 2029 under the current business plan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.